The study objective was to demonstrate the ability of our combined technologies (the Cocoon® Platform and 4D-Nucleofector® LV unit) to modify primary T-cells in a functionally-closed, automated fashion. In doing this, we provide an innovative solution that can help reduce costs, improve process efficiency, and increase final product quality for cell therapy manufacturing. Download our whitepaper to learn more.
You may also be interested in:
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center